COAG (Hemab Therapeutics Holdings) Loans Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
12 GF Score
Price $39.39
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Loans Receivable?

Hemab Therapeutics Holdings COAG -2.68% 12 Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates COAG with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Hemab Therapeutics Holdings's Loans Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Hemab Therapeutics Holdings Loans Receivable Related Terms

Hemab Therapeutics Holdings Loans Receivable Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Loans Receivable Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Loans Receivable
0.00 0.00

Hemab Therapeutics Holdings Quarterly Data
Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
COAG
12GF Score
Hemab Therapeutics Holdings Inc COAG
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Loans Receivable of $0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Loans Receivable too high?
Hemab Therapeutics Holdings' current Loans Receivable is $0.00 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Loans Receivable compare to ADMA and VCEL?
Hemab Therapeutics Holdings' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
12GF Score

Get the complete analysis for COAG

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.39
Price